Tuesday, January 07, 2020 10:48:23 AM
"Also, it became clear that mRNA seemed like a natural way of immunizing patients [who might otherwise not respond to immunotherapy]. Keytruda doesnt prime the immune system; mRNA would prime it."
https://xconomy.com/national/2019/01/16/merck-and-the-future-of-immuno-oncology-a-chat-with-roger-perlmutter/2/
___________
....
....
The key to partnerships comes from Wolchoks confirmation that Bavi â??creates a more immune active environment in which other treatments are able to have greater anti-tumor impact.â?
Look how this remark echoes and reinforces comments by Dr. Perlmutter, head of IO research at Merck, in an October ESMO article on Keytruda vs. Opdivo. Dr. Perlmutter explained that higher levels of PD-L1 confer a greater benefit from PD-1 blockers and, â??It turns out PD-L1 expression is just a marker for the presence of an immune response.â? Here is a quote from the article:
"So what does PD-L1 expression mean" and why do higher levels confer a greater benefit from PD-1 blockers?
"It turns out PD-L1 expression is just a marker for the presence of an immune response," explained Merck's head of research, Dr. Roger Perlmutter.
"Expression of PD-L1 is increased by immune response factors."
IN ENGLISH: PD-L1 is a signal that the immune system has been trying to fight the cancer. Or, as Perlmutter puts it, "Gee, there's already an immune response going on here."
http://www.cnbc.com/2016/10/07/bristol-myers-mercks-lung-cancer-treatments-square-off-this-weekend.html
This is why Wolchoks comment yesterday is so important when he confirmed that Bavi's MOA is to "create a more immune active environment":
DR. JEDD WOLCHOK STATES (11-14-16), Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact.
The really important part of the MSK poster, the part that will wake up all the BP decision makers, is not the mice survival data, but rather all the detailed work MSK did to confirm that Bavi is indeed triggering an upstream immune response, e.g. increase in CD8 T-cells, shift of macrophage from M2 to M1. MSK summarizes this "creation of a more active immune environment" in the 3rd & 4th bullet points of the Poster Conclusion. This is just what Dr. Perlmutter at Merck said was missing in the 80% of patients that don't respond to PD-1. To quote Perlmutter, Keytruda & Opdivo work better when the clinician can say "Gee, there's already an immune response going on here."
There is now strong evidence from the MSK poster and Wolchoks summary comments that Bavi triggers an upstream immune response. This will be a huge boost to the ongoing partnership talks.
...
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=126571427
___________
It would be relevant to review this post above in full, because some BP woke up ...enough, that even made John Springs Stafford wake up and risk lots ...
BP partnerships come in many forms to guarantees of CDMO contracts to etc etc .....and would it now, seem very odd that Scott Antonia to Dmitry Gabrilovich to Jason B Fleming to Jessica Frakes to many others all under the radar during Moffitt Cancer Center investigations ...Yes
Merck knows 100% that ones immune system must be primed at the most upstream level, the targeting of Phosphatidylserine is required.
Why did Rolf Brekken make a secret trip to China ....just weeks before Nan Fung Group backed Pivotal Bioventure back 30 day old Oncologie Inc with Eli Lilly backers etc
JP Morgan should fill in some blanks
Post # 324424 Brekken to China
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM